Anapalı, M. And Balkan, E. 2020. Use of Immun Checkpoint Inhibitor Ipilimumab in Renal Transplant Patients with Advanced Cancer: Is Risk/Benefit Ratio Dilemma?. New Trends in Medicine Sciences , vol.1, no.2 , 137-145.

Anapalı, M., & Balkan, E., (2020). Use of Immun Checkpoint Inhibitor Ipilimumab in Renal Transplant Patients with Advanced Cancer: Is Risk/Benefit Ratio Dilemma?. New Trends in Medicine Sciences , vol.1, no.2, 137-145.

Anapalı, Merve, And Eda BALKAN. "Use of Immun Checkpoint Inhibitor Ipilimumab in Renal Transplant Patients with Advanced Cancer: Is Risk/Benefit Ratio Dilemma?," New Trends in Medicine Sciences , vol.1, no.2, 137-145, 2020

Anapalı, Merve And Balkan, Eda. "Use of Immun Checkpoint Inhibitor Ipilimumab in Renal Transplant Patients with Advanced Cancer: Is Risk/Benefit Ratio Dilemma?." New Trends in Medicine Sciences , vol.1, no.2, pp.137-145, 2020

Anapalı, M. And Balkan, E. (2020) . "Use of Immun Checkpoint Inhibitor Ipilimumab in Renal Transplant Patients with Advanced Cancer: Is Risk/Benefit Ratio Dilemma?." New Trends in Medicine Sciences , vol.1, no.2, pp.137-145.

@article{article, author={Merve AYKAÇ And author={Eda BALKAN}, title={Use of Immun Checkpoint Inhibitor Ipilimumab in Renal Transplant Patients with Advanced Cancer: Is Risk/Benefit Ratio Dilemma?}, journal={New Trends in Medicine Sciences}, year=2020, pages={137-145} }